Payment overview · 2025
General Payments
$659.92
40 reported records · 12 companies
Healthcare provider profile · identity verified
Paul Demuro, DO
Allopathic & Osteopathic Physicians|Family Medicine · PASSAIC, NJ · NPI 1992883235
Verified facts
What the public records show
CMS Open Payments records show Paul Demuro, DO received $659.92 in general payments during 2025 across 40 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 19.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ingrezza, Ozempic, Rexulti, Xifaxan.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rexulti by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ingrezza by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 461 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $131.43 | 19.9% | 8 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $79.26 | 12.0% | 5 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $74.13 | 11.2% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $66.13 | 10.0% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $53.67 | 8.1% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $51.46 | 7.8% | 3 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $48.64 | 7.4% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $46.89 | 7.1% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $45.59 | 6.9% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $30.09 | 4.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.24 | 2.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.39 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $627.38 | 38 |
| Education | $32.54 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $131.43 | 8 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $127.80 | 7 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $79.26 | 5 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $66.13 | 4 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $48.64 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $45.59 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $45.59 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $32.54 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $30.09 | 2 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $18.24 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.39 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
124 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
461 | 56 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
20 | 20 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 792 | 148 |
| Pantoprazole Sodium | Pantoprazole Sodium | 569 | 108 |
| Amlodipine Besylate | Amlodipine Besylate | 566 | 113 |
| Eliquis | Apixaban | 461 | 56 |
| Metformin Hcl | Metformin Hcl | 396 | 76 |
| Losartan Potassium | Losartan Potassium | 378 | 75 |
| Levothyroxine Sodium | Levothyroxine Sodium | 298 | 54 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 289 | 75 |
| Gabapentin | Gabapentin | 284 | 54 |
| Furosemide | Furosemide | 271 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 218 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 215 | 46 |
| Donepezil Hcl | Donepezil Hcl | 211 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 209 | 36 |
| Omeprazole | Omeprazole | 207 | 37 |
| Carvedilol | Carvedilol | 205 | 36 |
| Torsemide | Torsemide | 202 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 187 | 34 |
| Entresto | Sacubitril/Valsartan | 174 | 18 |
| Lisinopril | Lisinopril | 172 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 164 | 36 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 144 | 27 |
| Mirtazapine | Mirtazapine | 143 | 26 |
| Levetiracetam | Levetiracetam | 132 | 19 |
| Memantine Hcl | Memantine Hcl | 132 | 22 |
| Potassium Chloride | Potassium Chloride | 129 | 25 |
| Montelukast Sodium | Montelukast Sodium | 128 | 25 |
| Meloxicam | Meloxicam | 126 | 33 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 125 | 28 |
| Jardiance | Empagliflozin | 124 | 14 |
| Azithromycin | Azithromycin | 117 | 84 |
| Januvia | Sitagliptin Phosphate | 115 | 15 |
| Divalproex Sodium | Divalproex Sodium | 109 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 106 | 29 |
| Sertraline Hcl | Sertraline Hcl | 100 | 15 |
| Tramadol Hcl | Tramadol Hcl | 100 | 35 |
| Famotidine | Famotidine | 98 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 98 | 40 |
| Zolpidem Tartrate | Zolpidem Tartrate | 97 | 22 |
| Prednisone | Prednisone | 96 | 60 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 95 | 45 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 88 | 19 |
| Alprazolam | Alprazolam | 87 | 27 |
| Glipizide Er | Glipizide | 86 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 85 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 84 | 17 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 82 | 11 |
| Glimepiride | Glimepiride | 81 | 18 |
| Xarelto | Rivaroxaban | 80 | 12 |
| Baclofen | Baclofen | 79 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 79 | 25 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 78 | 27 |
| Simvastatin | Simvastatin | 78 | 11 |
| Lactulose | Lactulose | 77 | 23 |
| Dropsafe Pen Needle | Pen Needle, Diabetic, Safety | 76 | 12 |
| Clonazepam | Clonazepam | 75 | 15 |
| Tradjenta | Linagliptin | 74 | 11 |
| Trazodone Hcl | Trazodone Hcl | 71 | 15 |
| Valsartan | Valsartan | 67 | 16 |
| Allopurinol | Allopurinol | 65 | 17 |
| Celecoxib | Celecoxib | 64 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 63 | 16 |
| Spironolactone | Spironolactone | 61 | 13 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 55 | 27 |
| Vascepa | Icosapent Ethyl | 55 | 11 |
| Novolog Flexpen | Insulin Aspart | 54 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 53 | 18 |
| Olanzapine | Olanzapine | 53 | suppressed |
| Pregabalin | Pregabalin | 53 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 52 | 11 |
| Ezetimibe | Ezetimibe | 50 | 11 |
| Alendronate Sodium | Alendronate Sodium | 49 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 49 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 48 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 48 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 47 | suppressed |
| Latanoprost | Latanoprost | 47 | suppressed |
| Naproxen | Naproxen | 47 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 46 | 32 |
| Finasteride | Finasteride | 46 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 45 | 20 |
| Clonidine Hcl | Clonidine Hcl | 44 | 12 |
| Glipizide | Glipizide | 44 | 13 |
| Ketoconazole | Ketoconazole | 44 | 17 |
| Linzess | Linaclotide | 44 | 11 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 40 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 39 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 39 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 39 | suppressed |
| Mupirocin | Mupirocin | 36 | 16 |
| Xifaxan | Rifaximin | 36 | suppressed |
| Atenolol | Atenolol | 35 | suppressed |
| Lumigan | Bimatoprost | 35 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 34 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 33 | suppressed |
| Nifedipine Er | Nifedipine | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 13 |
| Digoxin | Digoxin | 32 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 29 | suppressed |
| Cephalexin | Cephalexin | 29 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 28 | suppressed |
| Ibuprofen | Ibuprofen | 28 | suppressed |
| Lorazepam | Lorazepam | 28 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 16 |
| Diazepam | Diazepam | 26 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 25 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 24 | suppressed |
| Livalo | Pitavastatin Calcium | 24 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 23 | suppressed |
| Movantik | Naloxegol Oxalate | 23 | suppressed |
| Repaglinide | Repaglinide | 23 | suppressed |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Colchicine | Colchicine | 22 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 22 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 22 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 22 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 19 |
| Invokana | Canagliflozin | 21 | suppressed |
| Methimazole | Methimazole | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 14 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | 18 |
| Phenobarbital | Phenobarbital | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 20 | 13 |
| Nystatin | Nystatin | 20 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Phenytek | Phenytoin Sodium Extended | 19 | suppressed |
| Rexulti | Brexpiprazole | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Repatha Sureclick | Evolocumab | 18 | suppressed |
| Soaanz | Torsemide | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 17 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Calcium Acetate | Calcium Acetate | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 15 |
| Incruse Ellipta | Umeclidinium Bromide | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 15 | suppressed |
| Creon | Lipase/Protease/Amylase | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Prolia | Denosumab | 15 | suppressed |
| Timolol Maleate | Timolol Maleate | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Alphagan P | Brimonidine Tartrate | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Dupixent Pen | Dupilumab | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Budesonide | Budesonide | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Ozempic | Semaglutide | 13 | suppressed |
| Rivastigmine | Rivastigmine | 13 | suppressed |
| Securesafe Pen Needle | Pen Needle, Diabetic, Safety | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 12 | suppressed |
| Bicalutamide | Bicalutamide | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 12 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Insulin Lispro | Insulin Lispro | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Pyridostigmine Bromide Er | Pyridostigmine Bromide | 12 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 12 | 11 |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Acetazolamide | Acetazolamide | 11 | suppressed |
| Azathioprine | Azathioprine | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 11 | 11 |
| Chlordiazepoxide-Amitriptyline | Amitriptyline/Chlordiazepoxide | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Ingrezza | Valbenazine Tosylate | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Norvasc | Amlodipine Besylate | 11 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 11 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $659.92 · 40 records | Teva Pharmaceuticals USA, Inc. | AUSTEDO XR, CAPLYTA, INGREZZA, OTEZLA, Ozempic, REPATHA, REXULTI, VYNDAQEL, Veozah, XIFAXAN, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ingrezza play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error